396 related articles for article (PubMed ID: 8094290)
1. The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468.
Modjtahedi H; Styles JM; Dean CJ
Br J Cancer; 1993 Feb; 67(2):247-53. PubMed ID: 8094290
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction.
Modjtahedi H; Eccles S; Box G; Styles J; Dean C
Br J Cancer; 1993 Feb; 67(2):254-61. PubMed ID: 7679281
[TBL] [Abstract][Full Text] [Related]
3. Anti-EGFR monoclonal antibodies which act as EGF, TGF alpha, HB-EGF and BTC antagonists block the binding of epiregulin to EGFR-expressing tumours.
Modjtahedi H; Komurasaki T; Toyoda H; Dean C
Int J Cancer; 1998 Jan; 75(2):310-6. PubMed ID: 9462724
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGF receptor.
Modjtahedi H; Eccles SA; Box G; Styles J; Dean CJ
Cell Biophys; 1993; 22(1-3):129-46. PubMed ID: 7534211
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy with antibodies to the EGF receptor.
Dean C; Modjtahedi H; Eccles S; Box G; Styles J
Int J Cancer Suppl; 1994; 8():103-7. PubMed ID: 8194887
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.
Baselga J; Norton L; Masui H; Pandiella A; Coplan K; Miller WH; Mendelsohn J
J Natl Cancer Inst; 1993 Aug; 85(16):1327-33. PubMed ID: 8340945
[TBL] [Abstract][Full Text] [Related]
7. The binding of HB-EGF to tumour cells is blocked by mAbs which act as EGF and TGF alpha antagonists.
Modjtahedi H; Dean C
Biochem Biophys Res Commun; 1995 Feb; 207(1):389-97. PubMed ID: 7857293
[TBL] [Abstract][Full Text] [Related]
8. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5.
Modjtahedi H; Affleck K; Stubberfield C; Dean C
Int J Oncol; 1998 Aug; 13(2):335-42. PubMed ID: 9664130
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies to the EGF receptor act as betacellulin antagonists.
Modjtahedi H; Dean C
Biochem Biophys Res Commun; 1996 Apr; 221(3):625-30. PubMed ID: 8630011
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
11. The growth-response of human tumor-cell lines expressing the EGF receptor to treatment with EGF and or mabs that block ligand-binding.
Modjtahedi H; Styles J; Dean C
Int J Oncol; 1993 Aug; 3(2):237-43. PubMed ID: 21573354
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor efficacy of an anti-epidermal-growth-factor-receptor monoclonal antibody and its F(ab')2 fragment against high- and low-EGFR-expressing carcinomas in nude mice.
Tosi E; Valota O; Negri DR; Adobati E; Mazzoni A; Meazza R; Ferrini S; Colnaghi MI; Canevari S
Int J Cancer; 1995 Sep; 62(5):643-50. PubMed ID: 7665239
[TBL] [Abstract][Full Text] [Related]
13. EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins.
Wels W; Beerli R; Hellmann P; Schmidt M; Marte BM; Kornilova ES; Hekele A; Mendelsohn J; Groner B; Hynes NE
Int J Cancer; 1995 Jan; 60(1):137-44. PubMed ID: 7814146
[TBL] [Abstract][Full Text] [Related]
14. Expression of transforming growth factor alpha and its receptor in human neuroendocrine tumours.
Nilsson O; Wängberg B; Kölby L; Schultz GS; Ahlman H
Int J Cancer; 1995 Mar; 60(5):645-51. PubMed ID: 7860139
[TBL] [Abstract][Full Text] [Related]
15. Role of transforming growth factor-alpha (TGF-alpha) in basal and hormone-stimulated growth by estradiol, prolactin and progesterone in human and rat mammary tumor cells: studies using TGF-alpha and EGF receptor antibodies.
Ahmed SR; Badger B; Wright C; Manni A
J Steroid Biochem Mol Biol; 1991 Jun; 38(6):687-93. PubMed ID: 2064983
[TBL] [Abstract][Full Text] [Related]
16. Rat monoclonal antibodies to the external domain of the product of the C-erbB-2 proto-oncogene.
Styles JM; Harrison S; Gusterson BA; Dean CJ
Int J Cancer; 1990 Feb; 45(2):320-4. PubMed ID: 1689275
[TBL] [Abstract][Full Text] [Related]
17. Purification and characterization of a novel growth factor from human breast cancer cells.
Lupu R; Wellstein A; Sheridan J; Ennis BW; Zugmaier G; Katz D; Lippman ME; Dickson RB
Biochemistry; 1992 Aug; 31(32):7330-40. PubMed ID: 1324710
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth.
Harwerth IM; Wels W; Schlegel J; Müller M; Hynes NE
Br J Cancer; 1993 Dec; 68(6):1140-5. PubMed ID: 7903153
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor activity of monoclonal antibody CIBCNSH3 generated to the human EGF receptor.
Udayachander M; Dean CJ; Meenakshi AN; Sivakumar N; Babu PB; Sivakumar J
Hum Antibodies; 1997; 8(2):60-4. PubMed ID: 9289389
[TBL] [Abstract][Full Text] [Related]
20. Differential activation of ErbB receptors in the rat olfactory mucosa by transforming growth factor-alpha and epidermal growth factor in vivo.
Ezeh PI; Farbman AI
J Neurobiol; 1998 Nov; 37(2):199-210. PubMed ID: 9805267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]